GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Biotechnology

More

  • Apple shares hit 6-month highs Tuesday, 13 Aug 2013 | 1:30 PM ET
    Apple shares hit 6-month highs

    CNBC's Seema Mody reports the biggest movers in the Nasdaq including Apple, and biotech stocks.

  • Cloned horses may soon compete at US racetracks Tuesday, 13 Aug 2013 | 12:53 PM ET
    The head of cloning company Cryozootech, Eric Palmer, posing with a cloned horse Pieraz-Cryozootech-Stallion during its presentation to the press. The horse is a pure-bred Arab, from a castrated endurance champion, Pieraz.

    A judge ordered the American Quarter Horse Association to allow cloned horses to be entered into the breed's official registry, which could clear the way for the clones to race.

  • Seed giants try to change image of GMO crops Tuesday, 30 Jul 2013 | 11:21 AM ET
    A research biologist takes tissue samples from genetically modified corn plants inside a climate chamber housed in Monsanto agribusiness headquarters in St Louis.

    In an effort to clean up the image of genetically modified crops, major seed and crop science companies launched GMOAnswers.com to answer questions about so-called GMOs.

  • Biotech's boom, can it continue? Wednesday, 24 Jul 2013 | 2:35 PM ET
    Biotech's boom, can it continue?

    Biotech stocks are some of the best-performing S&P stocks this month. Chris Raymond, senior biotech analyst at Robert W. Baird, shares his top picks.

  • Health Care, Wealth, and Happiness Wednesday, 10 Jul 2013 | 12:18 PM ET
    Health Care, Wealth, and Happiness

    Health care stocks have been up almost across the board since 2010. Biotech and insurance names have been up triple digits. But political developments have put health care on a rockier path. CNBC's Kate Kelly breaks down the sector.

  • Genetic Modification: Seed Companies Fight Back Tuesday, 25 Jun 2013 | 4:10 PM ET

    Genetically modified seeds are used in corn and soybeans grown in the US, but the debate over the effects of tinkering with Mother Nature hasn't gone away.

  • Rising Rates Are Not a Bad Rx for Pharma: Ryan Thursday, 20 Jun 2013 | 3:27 PM ET

    Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.

  • Labels on bags of snack foods indicate they are non-GMO food products.

    Last year $2 billion worth of products were sold with a label saying they do not contain ingredients from genetically modified organisms, but the claim wasn't backed by regulators.

  • Genome Research Benefits Growing, Getting Cheaper Sunday, 16 Jun 2013 | 10:05 AM ET

    Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.

  • Whoa, Immortality by 2035? Mind-Blowing Investing Friday, 14 Jun 2013 | 5:15 PM ET

    Russian tycoon Dmitry Itskov is convening a meeting of the minds to explore the possibility of creating lifelike copies of humans, something he thinks is possible by 2035.

  • Unapproved Monsanto Frankenwheat Found in Oregon Wednesday, 29 May 2013 | 6:12 PM ET

    A strain of genetically engineered wheat never approved for sale or consumption was sprouting on a farm in Oregon, the Agriculture Department said Wednesday.

  • Nasdaq Check: Valeant-Bausch & Lomb Deal? Friday, 24 May 2013 | 1:30 PM ET
    Nasdaq Check: Pandora Shares Up

    Shares of Pandora are up after the company reported earnings, reports CNBC's Seema Mody. And there are reports a deal between Valeant Pharmaceuticals and Bausch & Lomb could be completed as early as next week.

  • Cramer’s Homework Uncovers Stock Concerns Friday, 26 Apr 2013 | 6:45 PM ET
    Cramer’s Homework: Less Familiar Stocks, but Less Attractive?

    Following is Cramer's homework. And he's concerned about a few of the stocks he's just researched.

  • Amgen's Stock Slammed by Disappointing Sales Tuesday, 23 Apr 2013 | 7:13 PM ET
    amgen-200.jpg

    Amgen's stock fell sharply in after-hours trading after it reported sales that fell short of Wall Street's expectations.

  • R&D For Your Portfolio: 3 Stocks in 3 Sectors Wednesday, 17 Apr 2013 | 7:44 AM ET
    R&D For Your Portfolio: 3 Stocks in 3 Sectors

    Mark Lehmann, JMP Securities president, provides investment strategies that include a biotech company with a promising drug to fight a rare form of Leukemia.

  • San Diego's Biotech Boom Wednesday, 10 Apr 2013 | 2:26 PM ET

    Road trip! Road trip! In the second stop, CNBC's Brian Sullivan reports on the biotech boom in San Diego.

  • San Diego Mayor: We've Diversified Wednesday, 10 Apr 2013 | 2:18 PM ET
    San Diego Mayor: We've Diversified

    San Diego Mayor Bob Filner (D) discusses the growing sectors in the city, rising home prices, and the burgeoning biotech industry.

  • Refining America's Finest City Wednesday, 10 Apr 2013 | 2:13 PM ET
    Refining America's Finest City

    CNBC's Jane Wells reports on business in San Diego, how the city has come back from the brink of bankruptcy, and the diversity of the economy. Just the same, taxes are among the highest in the country.

  • Why We're In San Diego Wednesday, 10 Apr 2013 | 2:00 PM ET
    Why We're In San Diego

    San Diego has the 2nd largest biotech industry in the U.S. CNBC's Brian Sullivan is there to check it out.

  • Biogen IDEC CEO on Multiple Sclerosis Pill Thursday, 28 Mar 2013 | 4:35 PM ET
    Biogen IDEC CEO on Multiple Sclerosis Pill

    Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.